BACKGROUND AND PURPOSE: ET is considered in selected patients with AIS with persistent arterial occlusion after receiving IVT. Limited data exist on the safety of IA high doses of UK and RT for ET. We investigated any correlation between IA doses of UK or RT and safety outcomes in patients who underwent ET. MATERIALS AND METHODS: We identified all patients from our stroke registry who received UK or RT for ET from 1998 to 2008. Demographics, baseline National Institutes of Health Stroke Scale scores, recanalization rates, rates of attempted MT, mortality, SICH, and discharge modified Rankin Scale scores were collected. RESULTS: Of 197 patients; 72 received UK and 125 received RT. More than 90% of patients in both groups had received prior IVT. The median IA dose of UK was 200,000 U (range, 25,000-1,500,000 U) and of RT was 2 mg (range, 1-8 mg). Concurrent MT was attempted in 59.7% of UK-treated patients and 72.0% of RT-treated patients, with SICH rates of 4.2% and 8.0%, respectively. Logistic regression adjusting for prior IVT and MT revealed no correlation between SICH and doses of UK (OR, 1.00; 95% CI, 0.99-1.00; P = .94) or RT (OR, 0.803; 95% CI, 0.48-1.33; P = .39). There was no correlation between mortality and doses of UK (OR, 1.00; 95% CI, 0.99-1.00; P = .51) or RT (OR, 1.048; 95% CI, 0.77-1.42; P = .75). CONCLUSIONS: High IA doses of UK and RT may be safe when given with or without MT in patients with AIS despite receiving a full dose of intravenous recombinant tissue plasminogen activator. These results need prospective validation.
BACKGROUND AND PURPOSE: ET is considered in selected patients with AIS with persistent arterial occlusion after receiving IVT. Limited data exist on the safety of IA high doses of UK and RT for ET. We investigated any correlation between IA doses of UK or RT and safety outcomes in patients who underwent ET. MATERIALS AND METHODS: We identified all patients from our stroke registry who received UK or RT for ET from 1998 to 2008. Demographics, baseline National Institutes of Health Stroke Scale scores, recanalization rates, rates of attempted MT, mortality, SICH, and discharge modified Rankin Scale scores were collected. RESULTS: Of 197 patients; 72 received UK and 125 received RT. More than 90% of patients in both groups had received prior IVT. The median IA dose of UK was 200,000 U (range, 25,000-1,500,000 U) and of RT was 2 mg (range, 1-8 mg). Concurrent MT was attempted in 59.7% of UK-treated patients and 72.0% of RT-treated patients, with SICH rates of 4.2% and 8.0%, respectively. Logistic regression adjusting for prior IVT and MT revealed no correlation between SICH and doses of UK (OR, 1.00; 95% CI, 0.99-1.00; P = .94) or RT (OR, 0.803; 95% CI, 0.48-1.33; P = .39). There was no correlation between mortality and doses of UK (OR, 1.00; 95% CI, 0.99-1.00; P = .51) or RT (OR, 1.048; 95% CI, 0.77-1.42; P = .75). CONCLUSIONS: High IA doses of UK and RT may be safe when given with or without MT in patients with AIS despite receiving a full dose of intravenous recombinant tissue plasminogen activator. These results need prospective validation.
Authors: Chelsea S Kidwell; Reza Jahan; Jeffry R Alger; Timothy J Schaewe; Judy Guzy; Sidney Starkman; Robert Elashoff; Jeffrey Gornbein; Val Nenov; Jeffrey L Saver Journal: Int J Stroke Date: 2012-09-13 Impact factor: 5.266
Authors: Adnan I Qureshi; Amir M Siddiqui; M Fareed K Suri; Stanley H Kim; Zulfiqar Ali; Abutaher M Yahia; Demetrius K Lopes; Alan S Boulos; Andrew J Ringer; Mustafa Saad; Lee R Guterman; L Nelson Hopkins Journal: Neurosurgery Date: 2002-11 Impact factor: 4.654
Authors: D L Tirschwell; W M Coplin; K J Becker; P Vogelzang; J Eskridge; D Haynor; W Cohen; D Newell; H R Winn; W T Longstreth Journal: Neurology Date: 2001-09-25 Impact factor: 9.910
Authors: Kyung Yul Lee; Dong Ik Kim; Seo Hyun Kim; Seung Ik Lee; Hae Woong Chung; Yong Woon Shim; Seung Min Kim; Ji Hoe Heo Journal: AJNR Am J Neuroradiol Date: 2004-10 Impact factor: 3.825
Authors: Maher Saqqur; Carlos A Molina; Abdul Salam; Muzaffar Siddiqui; Marc Ribo; Ken Uchino; Sergio Calleja; Zsolt Garami; Khaurshid Khan; Naveed Akhtar; Finton O'Rourke; Ashfaq Shuaib; Andrew M Demchuk; Andrei V Alexandrov Journal: Stroke Date: 2006-11-30 Impact factor: 7.914
Authors: R M Sugg; E A Noser; H M Shaltoni; N R Gonzales; M S Campbell; R Weir; E D Cacayorin; J C Grotta Journal: AJNR Am J Neuroradiol Date: 2006-04 Impact factor: 3.825
Authors: Pooja Khatri; Michael D Hill; Yuko Y Palesch; Judith Spilker; Edward C Jauch; Janice A Carrozzella; Andrew M Demchuk; Renee' Martin; Patrick Mauldin; Catherine Dillon; Karla J Ryckborst; Scott Janis; Thomas A Tomsick; Joseph P Broderick Journal: Int J Stroke Date: 2008-05 Impact factor: 5.266
Authors: N A Vora; R Gupta; A J Thomas; M B Horowitz; A H Tayal; M D Hammer; K Uchino; L R Wechsler; T G Jovin Journal: AJNR Am J Neuroradiol Date: 2007-08 Impact factor: 3.825
Authors: Adnan I Qureshi; Foad Abd-Allah; Aitziber Aleu; John J Connors; Ricardo A Hanel; Ameer E Hassan; Haitham M Hussein; Nazli A Janjua; Rakesh Khatri; Jawad F Kirmani; Mikael Mazighi; Heinrich P Mattle; Jefferson T Miley; Thanh N Nguyen; Gustavo J Rodriguez; Qaisar A Shah; Adnan H Siddiqui; Jose I Suarez; M Fareed K Suri; Reha Tolun Journal: J Vasc Interv Neurol Date: 2014-05